Take a look at our previous reports:

11. Income Taxes

The following table summarizes the income taxes recognized in profit or loss for the years ended December 31, 2025 and 2024.

Income taxes

 

Year ended December 31

(thousands of €)

2025

2024

Current tax expense

(792)

(1,301)

Deferred tax

19,413

3,104

Total income taxes

18,621

1,803

Current tax, consisting of corporate income taxes, and deferred tax income/cost (–) related to subsidiaries of our continuing operations working on a cost plus basis. The increase in deferred tax income in 2025 as compared to 2024 was primarily due to the reversal of the deferred tax liabilities linked to capitalized intangible assets related to the cell therapy business, as we recorded an impairment on these intangible assets.

Taxes recognized in profit or loss

For the purpose of the disclosure below corporate tax was calculated at 25% (2024: 25%) – which is the tax rate applied in Belgium – on the estimated assessable result for the year. The applied tax rate for other territorial jurisdictions was the tax rate that is applicable in these respective territorial jurisdictions on the estimated taxable result of the year.

Taxes recognized in profit or loss

 

Year ended December 31

(thousands of €)

2025

2024

Profit/loss (-) before tax

300,871

(3,085)

Income tax debit/credit (-), calculated using the Belgian statutory tax rate on the accounting profit/loss (-) before tax (theoretical)

75,218

(771)

Tax income (-)/expenses in income statement (effective)

(18,621)

(1,803)

Difference in tax expenses/income to explain

(93,839)

(1,032)

 

 

 

Effect of tax rates in other jurisdictions

(2,187)

(132)

Effect of non-taxable income

(3,774)

(5,247)

Effect of share-based payment expenses without tax impact

6,092

4,399

Effect of expenses/income (-) not subject to tax

(891)

52

Effect of non-tax-deductible expenses

3,472

1,117

Effect of recognition of previously non-recognized deferred tax assets

15

Effect of tax losses (utilized) reversed

(296)

Effect from under or over provisions in prior periods

336

13

Effect of non-recognition of deferred tax assets

(6,986)

(1,338)

Effect of derecognition of previously recognized deferred tax assets

827

89

Effect of use of innovation income deduction

(90,432)

Total explanations

(93,839)

(1,032)

Non-taxable income for the years ended December 31, 2025 and 2024 were related to non-taxable grants and tax credits.

Cell therapy
Cell therapy aims to treat diseases by restoring or altering certain sets of cells or by using cells to carry a therapy through the body. With cell therapy, cells are cultivated or modified outside the body before being injected into the patient. The cells may originate from the patient (autologous cells) or a donor (allogeneic cells)